The U.S. Food and Drug Administration (FDA) has approved Komzifti (ziftomenib), which is a type of treatment known as a menin ...

Expects to Submit Conditional Marketing Approval Application in Europe for Iopofosine I 131 in Refractory (post-BTKi) ...

Patients with refractory chronic cough who received twice-daily Haduvio for 21 days had decreases in cough frequency and ...

Typically, the ammunition to bring down an entire genre of movies is a series of box office flops. There can be other ...

Completed enrollment in soquelitinib atopic dermatitis Phase 1 trial extension cohort 4 (200 mg BID dose with 8-week treatment period) with data ...

Q3 2025 Earnings Call Transcript November 12, 2025 Autolus Therapeutics plc misses on earnings expectations. Reported EPS is ...

CEO Sergio Traversa highlighted a "standout year" for Relmada, citing "excellent product development progress" and a "recent successful capital raise." He emphasized the advancement of two clinical ...

And good afternoon, and welcome everyone to the Relmada Therapeutics, Inc. Third Quarter 2025 Conference Call. 2025 is ...

The investigation concluded that one of the officers had a vehicle driven directly at him and that the other mistook gunfire ...

The approval was based on data from the single-arm, open-label phase 2 KOMET-001 trial, which evaluated ziftomenib, a menin inhibitor, in adults with R/R AML with an NPM1 mutation.

Ulcerative colitis is a chronic, immune-mediated disorder of the colon, which is characterised by a relapsing–remitting course. Owing to the growing understanding of the immunopathogenesis of this ...

Q3 2025 Earnings Call Transcript November 4, 2025 Kura Oncology, Inc. misses on earnings expectations. Reported EPS is ...